Post-transplant lymphoproliferative disorder: a review

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Post-transplant lymphoproliferative disorder (PTLD) is a spectrum of Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative diseases.
• PTLD is a potentially fatal complication following hematopoietic stem cell transplantation (HSCT), often occurring early post-transplant.
• Established risk factors include HLA-mismatching, T-cell depletion, and antilymphocyte antibody use.

Purpose of the Study:

• To highlight the critical importance of early PTLD recognition in HSCT recipients.
• To discuss the clinical features and diagnostic approaches for PTLD.
• To explore emerging immune-based therapeutic strategies for PTLD management.

Main Methods:

• Review of clinical features and risk factors associated with PTLD in HSCT.
• Discussion of diagnostic surveillance techniques, including EBV antibody titers and PCR.
• Overview of current and investigational immune-based therapies.

Main Results:

• PTLD in HSCT patients is often rapidly progressive, necessitating prompt diagnosis.
• Surveillance methods like EBV PCR can aid in early detection in high-risk individuals.
• Immune-based therapies show promise for PTLD treatment and prophylaxis.

Conclusions:

• Early recognition and heightened clinical suspicion are paramount for diagnosing PTLD in HSCT settings.
• Novel immune-based treatments, including anti-B-cell antibodies and EBV-specific T cells, offer new therapeutic avenues.
• Continued research into PTLD pathogenesis and treatment is essential for improving patient outcomes.